Streetbeat News

Revenues

GENE

Genetic Technologies (GENE) is expanding its operations in North America, aiming to increase its market presence and enhance its service offerings in the region.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:01 pm

AAPL

DIA

MSFT

QQQ

SPY

On June 17th, U.S. stock markets hit record highs driven by technology stocks, with Apple and Microsoft rebounding. The NY Empire State Manufacturing Index showed improvement. The S&P 500 sectors mostly finished higher, led by industrials, information technology, and consumer discretionary stocks. Asian and European markets also saw gains, while crude oil prices dipped slightly.

Portfolio Pulse from Akanksha Bakshi

June 18, 2024 | 11:35 am

CGNT

Cognyte Software shares are trading higher after the company reported better-than-expected Q1 earnings and raised its FY25 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:30 am

ARKB

FBTC

HOOD

Bitcoin spot ETFs experienced $146 million in outflows on June 17, marking the fifth outflow day in six. Fidelity's ETF led with $92 million in withdrawals, followed by ARK 21Shares Bitcoin ETF with $50 million. This trend indicates ongoing market volatility and investor uncertainty.

Portfolio Pulse from Murtuza Merchant

June 18, 2024 | 11:20 am

MESA

Mesa Air Group expects to remain cash-flow neutral for the remainder of the fiscal year and looks forward to returning to consistent profitability in the future.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:20 am

PYPD

PolyPid provides an update on its SHIELD II trial, which aims to address the rising rates of surgical site infections (SSIs) post-COVID. With 250 out of 600 patients enrolled, an unblinded interim analysis will be conducted after 400 patients complete their 30-day follow-up. Top-line results are expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:18 am

CGNT

Cognyte Software has updated its financial outlook for the fiscal year ending January 31, 2025. The company expects revenue of $344 million at the midpoint, representing a 10% growth from the previous year, and an EPS loss of $0.07, which is better than the consensus estimate of a $0.13 loss.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:08 am

VNCE

Vince Holding expects Q2 fiscal 2024 sales to be flat to down low single digits compared to Q2 fiscal 2023. The company also projects a decline in operating margin by 500-750 basis points due to various factors including SG&A deleverage and severance expenses.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:08 am

IONS

Otsuka Pharmaceutical has obtained exclusive rights across the Asia-Pacific region for Ionis Pharmaceuticals' donidalorsen for hereditary angioedema. Ionis will receive a $20M upfront payment and milestone payments. Ionis will handle primary development, while Otsuka will manage territory-specific development, regulatory filings, and commercialization in the Asia-Pacific region and Europe.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:06 am

BSX

SILK

Boston Scientific expects its acquisition of Silk Road Medical to be immaterial to adjusted EPS in 2024 and 2025, but accretive thereafter. Silk Road Medical projects net revenue of $194-198 million in 2024, a 10-12% growth over the prior year. The transaction is expected to close in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:04 am